Literature DB >> 25953425

High-Pressure Transvenous Perfusion of the Upper Extremity in Human Muscular Dystrophy: A Safety Study with 0.9% Saline.

Zheng Fan1,2, Keith Kocis2,3,4, Robert Valley3,4, James F Howard1,2, Manisha Chopra1,2, Yasheng Chen5, Hongyu An5, Weili Lin5, Joseph Muenzer2,3, William Powers1,2.   

Abstract

We evaluated safety and feasibility of high-pressure transvenous limb perfusion in an upper extremity of adult patients with muscular dystrophy, after completing a similar study in a lower extremity. A dose escalation study of single-limb perfusion with 0.9% saline was carried out in nine adults with muscular dystrophies under intravenous analgesia. Our study demonstrates that it is feasible and definitely safe to perform high-pressure transvenous perfusion with 0.9% saline up to 35% of limb volume in the upper extremities of young adults with muscular dystrophy. Perfusion at 40% limb volume is associated with short-lived physiological changes in peripheral nerves without clinical correlates in one subject. This study provides the basis for a phase 1/2 clinical trial using pressurized transvenous delivery into upper limbs of nonambulatory patients with Duchenne muscular dystrophy. Furthermore, our results are applicable to other conditions such as limb girdle muscular dystrophy as a method for delivering regional macromolecular therapeutics in high dose to skeletal muscles of the upper extremity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25953425      PMCID: PMC4575535          DOI: 10.1089/hum.2015.023

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  26 in total

1.  Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: alpha-, beta-, gamma-, or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors.

Authors:  H Stedman; J M Wilson; R Finke; A L Kleckner; J Mendell
Journal:  Hum Gene Ther       Date:  2000-03-20       Impact factor: 5.695

2.  Clinical evaluator reliability for quantitative and manual muscle testing measures of strength in children.

Authors:  D M Escolar; E K Henricson; J Mayhew; J Florence; R Leshner; K M Patel; P R Clemens
Journal:  Muscle Nerve       Date:  2001-06       Impact factor: 3.217

3.  A laboratory evaluation of the level 1 rapid infuser (H1025) and the Belmont instrument fluid management system (FMS 2000) for rapid transfusion.

Authors:  Mark E Comunale
Journal:  Anesth Analg       Date:  2003-10       Impact factor: 5.108

4.  A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs.

Authors:  James E Hagstrom; Julia Hegge; Guofeng Zhang; Mark Noble; Vladimir Budker; David L Lewis; Hans Herweijer; Jon A Wolff
Journal:  Mol Ther       Date:  2004-08       Impact factor: 11.454

5.  The diagnostic value of intracompartmental pressure measurement, magnetic resonance imaging, and near-infrared spectroscopy in chronic exertional compartment syndrome: a prospective study in 50 patients.

Authors:  Johan G H van den Brand; Teresa Nelson; Egbert J M M Verleisdonk; Christian van der Werken
Journal:  Am J Sports Med       Date:  2005-02-16       Impact factor: 6.202

6.  An examination of some factors influencing creatine kinase in the blood of patients with muscular dystrophy.

Authors:  M J Jackson; J M Round; D J Newham; R H Edwards
Journal:  Muscle Nerve       Date:  1987-01       Impact factor: 3.217

7.  Definition of venous reflux in lower-extremity veins.

Authors:  Nicos Labropoulos; Jay Tiongson; Landon Pryor; Apostolos K Tassiopoulos; Steven S Kang; M Ashraf Mansour; William H Baker
Journal:  J Vasc Surg       Date:  2003-10       Impact factor: 4.268

8.  Ischemic and reperfusion injury of rat peripheral nerve.

Authors:  J D Schmelzer; D W Zochodne; P A Low
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

9.  0.5% versus 1.0% 2-chloroprocaine for intravenous regional anesthesia: a prospective, randomized, double-blind trial.

Authors:  Stephan C Marsch; Mathias Sluga; Wolfgang Studer; Jonas Barandun; Domenic Scharplatz; Wolfgang Ummenhofer
Journal:  Anesth Analg       Date:  2004-06       Impact factor: 5.108

10.  Activity, creatine kinase, and myoglobin in Duchenne muscular dystrophy: a clue to etiology?

Authors:  J M Florence; P T Fox; G J Planer; M H Brooke
Journal:  Neurology       Date:  1985-05       Impact factor: 9.910

View more
  9 in total

Review 1.  Progress with Recombinant Adeno-Associated Virus Vectors for Gene Therapy of Alpha-1 Antitrypsin Deficiency.

Authors:  Alisha M Gruntman; Terence R Flotte
Journal:  Hum Gene Ther Methods       Date:  2015-06       Impact factor: 2.396

Review 2.  Delivery of Adeno-Associated Virus Gene Therapy by Intravascular Limb Infusion Methods.

Authors:  Alisha M Gruntman; Terence R Flotte
Journal:  Hum Gene Ther Clin Dev       Date:  2015-09-10       Impact factor: 5.032

3.  Selective attachment of a microtubule interacting peptide to plasmid DNA via a triplex forming oligonucleotide for transfection improvement.

Authors:  Caroline Girardin; Delphine Maze; Cristine Gonçalves; Yann Thierry Le Guen; Kevin Pluchon; Chantal Pichon; Tristan Montier; Patrick Midoux
Journal:  Gene Ther       Date:  2022-07-07       Impact factor: 5.250

4.  Safety levels of systemic IL-12 induced by cDNA expression as a cancer therapeutic.

Authors:  Constanza Savid-Frontera; Maria E Viano; Natalia S Baez; Della Reynolds; Mariana Matellon; Howard A Young; Maria C Rodriguez-Galan
Journal:  Immunotherapy       Date:  2021-11-16       Impact factor: 4.196

5.  Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy.

Authors:  Caroline Le Guiner; Laurent Servais; Marie Montus; Thibaut Larcher; Bodvaël Fraysse; Sophie Moullec; Marine Allais; Virginie François; Maeva Dutilleul; Alberto Malerba; Taeyoung Koo; Jean-Laurent Thibaut; Béatrice Matot; Marie Devaux; Johanne Le Duff; Jack-Yves Deschamps; Inès Barthelemy; Stéphane Blot; Isabelle Testault; Karim Wahbi; Stéphane Ederhy; Samia Martin; Philippe Veron; Christophe Georger; Takis Athanasopoulos; Carole Masurier; Federico Mingozzi; Pierre Carlier; Bernard Gjata; Jean-Yves Hogrel; Oumeya Adjali; Fulvio Mavilio; Thomas Voit; Philippe Moullier; George Dickson
Journal:  Nat Commun       Date:  2017-07-25       Impact factor: 14.919

Review 6.  The golden retriever model of Duchenne muscular dystrophy.

Authors:  Joe N Kornegay
Journal:  Skelet Muscle       Date:  2017-05-19       Impact factor: 4.912

7.  DNA-Mediated Gene Therapy in a Mouse Model of Limb Girdle Muscular Dystrophy 2B.

Authors:  Julia Ma; Christophe Pichavant; Haley du Bois; Mital Bhakta; Michele P Calos
Journal:  Mol Ther Methods Clin Dev       Date:  2017-10-24       Impact factor: 6.698

8.  An Isolated Limb Infusion Method Allows for Broad Distribution of rAAVrh74.MCK.GALGT2 to Leg Skeletal Muscles in the Rhesus Macaque.

Authors:  Rui Xu; Ying Jia; Deborah A Zygmunt; Megan L Cramer; Kelly E Crowe; Guohong Shao; Agatha E Maki; Haley N Guggenheim; Benjamin C Hood; Danielle A Griffin; Ellyn Peterson; Brad Bolon; John P Cheatham; Sharon L Cheatham; Kevin M Flanigan; Louise R Rodino-Klapac; Louis G Chicoine; Paul T Martin
Journal:  Mol Ther Methods Clin Dev       Date:  2018-07-14       Impact factor: 6.698

9.  Plasmid-Mediated Gene Therapy in Mouse Models of Limb Girdle Muscular Dystrophy.

Authors:  Tuhin K Guha; Christophe Pichavant; Michele P Calos
Journal:  Mol Ther Methods Clin Dev       Date:  2019-10-14       Impact factor: 6.698

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.